Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer

Genomic amplification of 19q12 occurs in several cancer types including ovarian cancer where it is associated with primary treatment failure. We systematically attenuated expression of genes within the minimally defined 19q12 region in ovarian cell lines using short-interfering RNAs (siRNA) to identify driver oncogene(s) within the amplicon. Knockdown of CCNE1 resulted in G1/S phase arrest, reduced cell viability and apoptosis only in amplification-carrying cells. Although CCNE1 knockdown increased cisplatin resistance in short-term assays, clonogenic survival was inhibited after treatment. Gain of 20q11 was highly correlated with 19q12 amplification and spanned a 2.5 Mb region including TPX2, a centromeric protein required for mitotic spindle function. Expression of TPX2 was highly correlated with gene amplification and with CCNE1 expression in primary tumors. siRNA inhibition of TPX2 reduced cell viability but this effect was not amplicon-dependent. These findings demonstrate that CCNE1 is a key driver in the 19q12 amplicon required for survival and clonogenicity in cells with locus amplification. Co-amplification at 19q12 and 20q11 implies the presence of a cooperative mutational network. These observations have implications for the application of targeted therapies in CCNE1 dependent ovarian cancers.

[1]  J. Stockman,et al.  A Network Model of a Cooperative Genetic Landscape in Brain Tumors , 2011 .

[2]  Kylie L. Gorringe,et al.  Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer , 2010, PloS one.

[3]  Kentaro Nakayama,et al.  Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer , 2010, Cancer.

[4]  I. Shih,et al.  Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase , 2010, Modern Pathology.

[5]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[6]  Claudia Marchetti,et al.  First-line treatment of advanced ovarian cancer: current research and perspectives , 2010, Expert review of anticancer therapy.

[7]  M. Meyerson,et al.  Amplification of chromosomal segment 4q12 in non-small cell lung cancer , 2009, Cancer biology & therapy.

[8]  J. Trent,et al.  Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells , 2009, Clinical Cancer Research.

[9]  A. Regev,et al.  SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas , 2009, Nature Genetics.

[10]  K. Keyomarsi,et al.  Post-translational modification and stability of low molecular weight cyclin E , 2009, Oncogene.

[11]  Gordon B Mills,et al.  Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer , 2009, Clinical Cancer Research.

[12]  Laura Tolosi,et al.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.

[13]  I. Jonassen,et al.  Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation , 2009, Proceedings of the National Academy of Sciences.

[14]  J. Fridlyand,et al.  Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis , 2009, Oncogene.

[15]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[16]  Joshy George,et al.  Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.

[17]  Zoltan Dezso,et al.  Genome-wide functional synergy between amplified and mutated genes in human breast cancer. , 2008, Cancer research.

[18]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[19]  Li Li,et al.  High‐resolution genomic and expression analyses of copy number alterations in breast tumors , 2008, Genes, chromosomes & cancer.

[20]  W. Chia,et al.  Drosophila neuroblast asymmetric divisions: cell cycle regulators, asymmetric protein localization, and tumorigenesis , 2008, The Journal of cell biology.

[21]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[22]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[23]  R. Aebersold,et al.  S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling. , 2007, Molecular cell.

[24]  Ian G. Campbell,et al.  High-Resolution Single Nucleotide Polymorphism Array Analysis of Epithelial Ovarian Cancer Reveals Numerous Microdeletions and Amplifications , 2007, Clinical Cancer Research.

[25]  I. Shih,et al.  Amplicon profiles in ovarian serous carcinomas , 2007, International journal of cancer.

[26]  Wenwu Cui,et al.  qPrimerDepot: a primer database for quantitative real time PCR , 2006, Nucleic Acids Res..

[27]  G. Amann,et al.  Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. , 2006, American journal of clinical pathology.

[28]  Rui Li,et al.  Comprehensive analysis of 19q12 amplicon in human gastric cancers , 2006, Modern Pathology.

[29]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Hengartner,et al.  URI-1 is required for DNA stability in C. elegans , 2006, Development.

[31]  B. Clurman,et al.  Cyclin E in normal and neoplastic cell cycles , 2005, Oncogene.

[32]  Kylie L. Gorringe,et al.  Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization , 2005, Genes, chromosomes & cancer.

[33]  R. Sutherland,et al.  Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix–loop–helix protein Id1 , 2005, Oncogene.

[34]  I. Bedrosian,et al.  Cyclin E deregulation alters the biologic properties of ovarian cancer cells , 2004, Oncogene.

[35]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[36]  Yan Geng,et al.  Cyclin E Ablation in the Mouse , 2003, Cell.

[37]  L. Morrison,et al.  Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. , 2003, Cancer research.

[38]  K. Keyomarsi,et al.  Cyclin E and Its Low Molecular Weight Forms in Human Cancer and as Targets for Cancer Therapy , 2003, Cancer biology & therapy.

[39]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[40]  R. Kuick,et al.  Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. , 2000, Cancer research.

[41]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[42]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  H. Yokozaki,et al.  Frequent Amplification of the Cyclin E Gene in Human Gastric Carcinomas , 1995, Japanese journal of cancer research : Gann.